Dr. Nagy generated Canada’s first embryonic stem cell lines and discovered the first efficient non-viral method to reprogram somatic cells in to iPSCs. He was among the first who discovered the “dark side” of stem cell generation by finding that the establishment of these cells are associated with genetic damage. This discovery lead him to focus on finding a way to eliminate the potential risk of tumor formation if stem cell derived therapeutic cells are used in patients. He is a Canada Research Chair in Stem Cells and Regeneration as well as a senior scientific investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System and a Professor in the Department of Obstetrics & Gynaecology and Institute of Medical Science at the University of Toronto. Dr. Nagy is also a Professor at the Monash University, Melbourne, Australia and runs a second laboratory in the Australian Regenerative Medicine Institute (ARMI)
Dr. Keating is an internationally recognized leader in blood and marrow transplantation and cell therapy. He is a Professor of Medicine and of Biomedical Engineering at the University of Toronto and established what has become the largest stem cell transplantation program in Canada at the University Health Network. He held the position of Chief, Medical Services at Princess Margaret Hospital for a decade and was the Division Director of Hematology at the University of Toronto as well as the first incumbent of the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation. He is a past President of the American Society of Hematology and a past President of the American Society for Blood and Marrow Transplantation. He has served in a number of advisory roles at the US National Institutes of Health and more recently for the New Organ Alliance and NASA. Dr. Keating is a co-Founder of CellCAN, a consortium of cell manufacturing centres and their investigators across Canada and serves as Chair of its Steering Committee. His research and clinical interests focus on cell-based tissue regeneration, anti-cancer cell therapy, and blood and marrow transplantation. He has conducted laboratory, translational and clinical research in these areas, particularly on the biology and clinical application of mesenchymal stromal cells and NK cells.
As COO of panCELLa, Mr. Greg Hood reports directly to the Board. Greg was recruited because of his demonstrated skill as a visionary and strategic planner ideal at leading organizations and managing shareholder value. While working and living in Canada, the US, London, and the Asia-Pacific, he consistently demonstrated success in developing and scaling diverse operations, start-ups, joint ventures, and multi-nationals. Most recently Greg was the CEO of a commercialization centre and one of the largest technology incubators in Atlantic Canada. With extensive experience in raising venture capital and private equity in the North Americas in a variety of highly-competitive markets and economies, Greg is an innovative and transformational leader renown for recruiting and retaining high-caliber individuals. Having been an active participant at the Board level for various organizations, Greg holds a Bachelor in Economics from Queen’s University, a Bachelor of Commerce from the University of Windsor, and has been Top-Graded by GH Smart and Associates as an A+ caliber leader.
Reporting directly to Dr. Nagy, Dr. Monetti is responsible for the day-to- day management and operation of panCELLa’s lab. A molecular biologist with an interest in transgenics, genome engineering and ES cells, Dr. Monetti is a graduate of the Università degli Studi di Milano. Since 2003, upon obtaining his PhD, Dr. Monetti has worked with Dr. Nagy at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital. His work has involved developing a site-specific DNA insertion strategy based on the integrase PhiC31 and the use of multiple recombinases such as Cre, Dre, Flp and PhiC31 to replace targeted genes and detect intersectional gene expression in the mouse. More recently he specialized in genome engineering human ES cells using different techniques including CRISPR/Cas9. Dr. Monetti is one of the inventors of panCELLa’s exclusive FailSafe Technology.
As the Manager of Operations, Lisa brings her flair for planning, project management, communications, and marketing to panCELLa. Prior to joining panCELLa, Lisa worked with a commercialization centre and a number of fledgling organizations where she successfully built up teams as well as organizations. Lisa graduated from the University of Toronto’s Faculty of Library and Information Science with an MLS and having worked with an institutional information provider and in academic and public libraries, Lisa is an experienced and resourceful intelligence-gatherer who is also responsible for providing the panCELLa team with complex quantitative analysis and metrics.